En undersøgelse for at lære om undersøgelsesmedicinen PF-07934040, når den gives alene eller sammen med andre anti-cancerterapier hos mennesker med avancerede solide tumorer, der har en genetisk mutation.
En fase 1 åben-label undersøgelse af PF-07934040 som et enkelt middel og i kombination med andre målrettede midler hos deltagere med avancerede solide tumorer, der rummer mutationer i KRAS-genet
The purpose of this study is to learn about the safety and effects of the study medicine alone or when given together with other anti-cancer therapies. This study also aims to find the best dose.
This study is seeking participants who have solid tumors (a mass of abnormal cells that forms a lump or growth in the body) that:
- are advanced (cancer that doesn't disappear or stay away with treatment) and
- have a KRAS gene mutation (a change in the DNA of the KRAS gene that can cause cells to grow in very high numbers).
This includes (but limited to) the following cancer types:
Non-Small Cell Lung Cancer (NSCLC): It's a type of lung cancer where the cells grow slowly but often spread to other parts of the body.
Colorectal Cancer (CRC): This is a disease where cells in the colon (a part of large intestine) or rectum grow out of control.
Pancreatic ductal adenocarcinoma (PDAC): This is a cancer that starts in the ducts of the pancreas but can spread quickly to other parts of the body. Pancreas is a long, flat gland that lies in the abdomen behind the stomach. Pancreas creates enzymes that help with digestion. It also makes hormones that can help control your blood sugar levels.
All participants in this study will take the study medication (PF-07934040) as pill by mouth twice a day repeating for 21-day or 28-day cycles.
Depending on which part of the study participants are enrolled into they will receive the study medication (PF-07934040 alone or in combination with other anti-cancer medications). These anti-cancer medications will be given in the study clinic by intravenous (IV) that is directly injected into the veins at various times (depending on the treatment) during the 21-day or 28-day cycle.
Participants can continue to take the study medication (PF-07934040) and the combination anti-cancer therapy until their cancer is no longer responding.
The study will look at the experiences of people receiving the study medicines. This will help see if the study medicines are safe and effective.
Participants will be involved in this study for up to 4 years. During this time, they will come into the clinic between 1 to 4 times in each 21-day or 28-day cycle. After they have stopped taking the study medication (at about at 2 years) they will be followed for another two years to see how they are doing.
Studieoversigt
Status
Intervention / Behandling
- Medicin: PF-07934040
- Kombinationsprodukt: Gemcitabine
- Kombinationsprodukt: Nab-paclitaxel
- Kombinationsprodukt: Cetuximab
- Kombinationsprodukt: Fluorouracil
- Kombinationsprodukt: Oxaliplatin
- Kombinationsprodukt: Leucovorin
- Kombinationsprodukt: Bevacizumab
- Kombinationsprodukt: Pembrolizumab
- Kombinationsprodukt: Sasanlimab
- Kombinationsprodukt: pemetrexed
- Kombinationsprodukt: Cisplatin
- Kombinationsprodukt: Paclitaxel
- Kombinationsprodukt: Carboplatin
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 1
Kontakter og lokationer
Studiesteder
-
-
Arkansas
-
Fayetteville, Arkansas, Forenede Stater, 72703
- Highlands Oncology Group, PA
-
Rogers, Arkansas, Forenede Stater, 72758
- Highlands Oncology Group, PA
-
Springdale, Arkansas, Forenede Stater, 72762
- Highlands Oncology Group
-
-
California
-
Duarte, California, Forenede Stater, 91010
- City of Hope (City of Hope National Medical Center, City of Hope Medical Center)
-
Duarte, California, Forenede Stater, 91010
- City of Hope Investigational Drug Service (IDS)
-
-
Colorado
-
Aurora, Colorado, Forenede Stater, 80045
- University of Colorado Hospital - Anschutz Outpatient Pavilion
-
Aurora, Colorado, Forenede Stater, 80045
- University of Colorado Hospital - Anschutz Inpatient Pavilion (AIP)
-
Aurora, Colorado, Forenede Stater, 80045
- University of Colorado Hospital- Anschutz Cancer Pavilion (ACP)
-
Aurora, Colorado, Forenede Stater, 80045
- University of Colorado Hospital
-
-
District of Columbia
-
Washington D.C., District of Columbia, Forenede Stater, 20016
- Sibley Memorial Hospital
-
-
Michigan
-
Grand Rapids, Michigan, Forenede Stater, 49546
- START Midwest
-
-
Missouri
-
City of Saint Peters, Missouri, Forenede Stater, 63376
- Siteman Cancer Center - St Peters
-
Creve Coeur, Missouri, Forenede Stater, 63141
- Siteman Cancer Center - West County
-
Florissant, Missouri, Forenede Stater, 63031
- Siteman Cancer Center - North County
-
St Louis, Missouri, Forenede Stater, 63110
- Barnes-Jewish Hospital
-
St Louis, Missouri, Forenede Stater, 63110
- Washington University School of Medicine
-
St Louis, Missouri, Forenede Stater, 63129
- Siteman Cancer Center - South County
-
St Louis, Missouri, Forenede Stater, 63108
- Siteman Cancer Center
-
-
North Carolina
-
Durham, North Carolina, Forenede Stater, 27710
- Duke University Medical Center
-
Durham, North Carolina, Forenede Stater, 27710
- Duke University Medical Center, lnvestigational Chemotherapy Service
-
-
Ohio
-
Cincinnati, Ohio, Forenede Stater, 45219
- University of Cincinnati Medical Center
-
Cleveland, Ohio, Forenede Stater, 44195
- Cleveland Clinic Taussig Cancer Center
-
West Chester, Ohio, Forenede Stater, 45069
- West Chester Hospital
-
-
Rhode Island
-
Providence, Rhode Island, Forenede Stater, 02903
- Rhode Island Hospital
-
Providence, Rhode Island, Forenede Stater, 02906
- Miriam Hospital
-
-
Texas
-
Houston, Texas, Forenede Stater, 77030
- University of Texas MD Anderson Cancer Center
-
-
-
-
-
Rio Piedras, Puerto Rico, 00935
- Pan American Center for Oncology Trials, LLC
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Histological or cytological diagnosis of advanced, unresectable, and/or metastatic or relapsed/refractory solid tumor.
ECOG PS 0 or 1
-
Presence of at least 1 measurable lesion based on RECIST version 1.1 that has not been previously irradiated.
-
Documentation of mutated KRAS gene
- PDAC, CRC, Other tumor types: Confirmed KRAS mutation, any variant
- NSCLC: Confirmed KRAS mutation, any variant except previously treated G12C. If driver mutation, must have failed precision medicine therapy [eg, inhibitors of epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), c-ros oncogene 1 (ROS1), and others].
-
Part 1 and Part 2a: Participant must have progressed on standard treatment(s) for which no additional, effective therapy is available.
- PDAC (2-3L): Participants must have received and radiologically progressed on prior lines of systemic therapy for metastatic pancreatic adenocarcinoma. If participants received prior neoadjuvant or adjuvant chemotherapy and progressed within 6 months of the last dose, then this should be considered as a prior line of systemic therapy.
- NSCLC (2-3L): Participants must have received prior lines of anti-cancer treatment and progressed on at least a platinum-containing chemotherapy regimen or ICI. Participants may have had only one or two prior lines of therapy in the advanced/metastatic setting. For participants with EGFR, ALK, or other genomic tumor alterations, participants must have progressed on approved therapy for these alterations.
- CRC (2-3L): Participants must have had one or two prior lines of therapy for mCRC. For either one or two prior treatments, these regimens must have included a fluoropyrimidine, oxaliplatin, and/or irinotecan for one prior treatment, exposure to VEGF/VEGF receptor (VEGFR) inhibitor is optional;
- Other tumors: Participants, in the judgment of the investigator, must have progressed or become intolerant to all available standard therapies, or have refused such therapy.
-
Part 2b:
- PDAC (1L) Cohort A2: Participants must not have received prior chemotherapy for metastatic disease. Participant could have received neoadjuvant therapy, adjuvant therapy, or adjuvant chemo-radiotherapy. If relapse occurred within 6 months of last dose of adjuvant treatment or neoadjuvant therapy, the participant would be considered 2L, and not 1L.
- CRC (2-3L) Cohort B2: Participants must have had one or two prior systemic treatment regimens for mCRC. For either one or two prior treatments, these regimens must have included a fluoropyrimidine, irinotecan, oxaliplatin; for one prior treatment, exposure to a VEGF/VEGF receptor (VEGFR) inhibitor is optional.
- CRC (1L) Cohort B3/B4: Participants must not have received prior therapy for metastatic disease and not be a candidate for other targeted therapy or immunotherapy. Participant could have received neoadjuvant therapy, adjuvant therapy, or adjuvant chemo-radiotherapy. If relapse occurred within 6 months of last dose of adjuvant or neoadjuvant therapy, then the participant would be considered 2L, and not 1L.
- NSCLC (1L) Cohort C2: Participants must have a TPS ≥50% and must not have received prior systemic treatment setting.
- NSCLC (1L) Cohort C3: Participants with any TPS and must not have received prior systemic treatment setting.
Exclusion Criteria:
-
Active or history of pneumonitis/ILD or pulmonary fibrosis requiring treatment with systemic steroid therapy.
-
Diagnosis of immunodeficiency or an active autoimmune disease that require systemic treatment with chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy in the past 2 years.
-
Sensory peripheral neuropathy ≥Grade 2
-
Active or history of clinically significant gastrointestinal (GI) disease (including but not limited to inflammatory GI disease [eg, ulcerative colitis, Crohn's disease, inflammatory bowel disease], immune-mediated colitis, peptic ulcer disease, GI bleeding, chronic diarrhea) and other conditions that are unresolved and/or may increase the risk associated with study participation or study treatment administration.
-
Active bleeding disorder, including GI bleeding, as evidenced by hematemesis, significant hemoptysis or melena in the past 6 months.
-
Major surgery or completion of radiation therapy ≤4 weeks prior to enrollment/randomization or radiation therapy that included >30% of the bone marrow.
-
Known sensitivity or contraindication to any component of study intervention (PF 07934040, gemcitabine, nab-paclitaxel, cetuximab, bevacizumab, FOLFOX, 5-FU, pembrolizumab, cisplatin, carboplatin, pemetrexed, SHP2 inhibitor(s), cyclin-dependent kinase (CDK) inhibitor(s), antibody drug conjugates (ADCs) or EGFR inhibitor(s)).
-
Hematologic abnormalities.
-
Renal impairment.
- Hepatic abnormalities.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Sekventiel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Part 1
PF-07934040 Monotherapy Dose Escalation PF-07934040 monotherapy at prescribed dose and frequency in 28-day cycles |
panKRAS inhibitor
Andre navne:
|
|
Eksperimentel: Part 2a Cohort A1
Monotherapy dose expansion in 2-3L PDAC. PF-07934040 at prescribed dose and frequency in 28-day cycles |
panKRAS inhibitor
Andre navne:
|
|
Eksperimentel: Part 2a Cohort B1
Monotherapy dose expansion in 2-3L CRC. PF-07934040 at prescribed dose and frequency in 28-day cycles |
panKRAS inhibitor
Andre navne:
|
|
Eksperimentel: Part 2a Cohort C1
Monotherapy dose expansion in 2-3L NSCLC. PF-07934040 at prescribed dose and frequency in 28-day cycles |
panKRAS inhibitor
Andre navne:
|
|
Eksperimentel: Part 2a Cohort D1
Monotherapy dose expansion in Other Indications. PF-07934040 at prescribed dose and frequency in 28-day cycles |
panKRAS inhibitor
Andre navne:
|
|
Eksperimentel: Part 2b Cohort A2
Combination (PF-07934040 + Gemcitabine + Nab-paclitaxel) dose escalation/expansion in 1L PDAC. Prescribed dose and frequency in 28-day cycles |
panKRAS inhibitor
Andre navne:
Chemotherapy (antimetabolite)
Andre navne:
Taxane-type Chemotherapy
Andre navne:
|
|
Eksperimentel: Part 2b Cohort B2
Combination (PF-07934040 + Cetuximab) dose escalation/expansion in 2-3L CRC Prescribed dose and frequency in 28-day cycles |
panKRAS inhibitor
Andre navne:
Monoclonal Antibody (EGFR Inhibitor)
Andre navne:
|
|
Eksperimentel: Part 2b Cohort B3
Combination (PF-07934040 + FOLFOX + Bevacizumab) dose escalation/expansion in 1L CRC Prescribed dose and frequency in 28-day cycles |
panKRAS inhibitor
Andre navne:
Part of FOLFOX chemotherapy regimen cytotoxic chemotherapy (antimetabolite and pyrimidine analog)
Andre navne:
Part of FOLFOX Chemotherapy Regimen platinum based compound (alkylating agent)
Andre navne:
Part of FOLFOX chemotherapy regimen Folic Acid Analog
Andre navne:
VEG-F inhibitor
Andre navne:
|
|
Eksperimentel: Part 2b Cohort B4
Combination (PF-07934040 + FOLFOX + Cetuximab) dose escalation/expansion in 1L CRC Prescribed dose and frequency in 28-day cycles |
panKRAS inhibitor
Andre navne:
Monoclonal Antibody (EGFR Inhibitor)
Andre navne:
Part of FOLFOX chemotherapy regimen cytotoxic chemotherapy (antimetabolite and pyrimidine analog)
Andre navne:
Part of FOLFOX Chemotherapy Regimen platinum based compound (alkylating agent)
Andre navne:
Part of FOLFOX chemotherapy regimen Folic Acid Analog
Andre navne:
|
|
Eksperimentel: Part 2b Cohort C2
Combination (PF-07934040 + Pembro or Sasanlimab) dose escalation/expansion in 1L NSCLC (TPS ≥ 50%) Prescribed dose and frequency in 21-day cycles (for pembro) or 28-day cycles (for sasanlimab) |
panKRAS inhibitor
Andre navne:
immune checkpoint inhibitor (PD-1 inhibitor)
Andre navne:
immune checkpoint inhibitor (PD-1 inhibitor)
Andre navne:
|
|
Eksperimentel: Part 2b Cohort C3
Combination (PF-07934040 + Pembro + Platinum Chemo) dose escalation/expansion in 1L NSCLC (any TPS) Prescribed dose and frequency in 21-day cycles |
panKRAS inhibitor
Andre navne:
immune checkpoint inhibitor (PD-1 inhibitor)
Andre navne:
Can be used in Platinum-based Chemotherapy regimen Antimetabolite
Andre navne:
Can be used as part of Platinum-based chemotherapy regimen Platinum-based antineoplastic (alkylating agent)
Andre navne:
Can be used in Platinum-based chemotherapy regimen Taxane
Andre navne:
Can be used as part of a platinum-based chemotherapy regimen platinum containing compound (alkylating agent)
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Part 1 & 2: Incidence of Adverse Events (AEs)
Tidsramme: Start of treatment up to 30 days after last dose or start of new anticancer therapy (whichever occurs first)
|
An adverse event (AE) was any untoward medical occurrence in a participant who received study medication without regard to possibility of causal relationship to it. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/ incapacity; congenital anomaly. AEs included both serious and all non-serious AEs. |
Start of treatment up to 30 days after last dose or start of new anticancer therapy (whichever occurs first)
|
|
PART 1 & 2: Number of participants with laboratory abnormalities
Tidsramme: From start of treatment up to 30 days after last dose or start of new anticancer therapy, whichever occurred first
|
Number of participants with laboratory test abnormalities. Laboratory test parameters included hematology, coagulation, liver function, renal function, electrolytes, clinical chemistry, and urinalysis (dipstick and microscopy). |
From start of treatment up to 30 days after last dose or start of new anticancer therapy, whichever occurred first
|
|
Part 1: Number of participants with Dose-limiting toxicities (DLT)
Tidsramme: Baseline up to 28 days
|
Any of the prespecified AEs that are attributable to one, the other, or both study treatments, occurring in the DLT observation period are considered DLTs, excluding toxicities clearly due to underlying disease or extraneous causes |
Baseline up to 28 days
|
|
Part 2: Objective Response - Number of Participants With Objective Response (alone or in combination)
Tidsramme: Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion, approximately 2 years'
|
Percentage of participants with objective response-based assessment of complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST v1.1) for overall response rate (ORR), progression free survival (PFS), and overall survivor (OS) assessed by the Investigator. |
Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion, approximately 2 years'
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Part 1 & 2: Maximum Observed Serum Concentration (Cmax)
Tidsramme: baseline through end of Cycle 1 (All cycles are 28 days except part 2b Cohort C2 which are 21 days)
|
Evaluate the single and multiple dose PK of PF-07934040 as monotherapy, or in combination with other anti-tumor agents. |
baseline through end of Cycle 1 (All cycles are 28 days except part 2b Cohort C2 which are 21 days)
|
|
Part 1& 2: Time to Reach Maximum Observed Serum Concentration (Tmax)
Tidsramme: Baseline through end of Cycle 1 (All cycles are 28 days except part 2b Cohort C2 which are 21 days)
|
Evaluate the single and multiple dose PK of PF-07934040 as monotherapy, or in combination with other anti-tumor agents. |
Baseline through end of Cycle 1 (All cycles are 28 days except part 2b Cohort C2 which are 21 days)
|
|
Part 1 & 2: Serum Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)
Tidsramme: Baseline through end of Cycle 1 (All cycles are 28 days except part 2b Cohort C2 which are 21 days)
|
Evaluate the single and multiple dose PK of PF-07934040 as monotherapy, or in combination with other anti-tumor agents. |
Baseline through end of Cycle 1 (All cycles are 28 days except part 2b Cohort C2 which are 21 days)
|
|
Part 1 & 2: Changes in pERK levels
Tidsramme: Baseline through end of Cycle 1 (All cycles are 28 days except part 2b Cohort C2 which are 21 days)
|
Evaluates the intended mechanism of action (MoA) modulation of KRAS inhibition and target engagement effect of PF-07934040 in peripheral blood of participants with advanced solid tumor malignancies. |
Baseline through end of Cycle 1 (All cycles are 28 days except part 2b Cohort C2 which are 21 days)
|
|
Part 1: Objective Response - Number of Participants With Objective Response
Tidsramme: Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion, approximately 2 years
|
Percentage of participants with objective response-based assessment of complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST v1.1) assessed by the Investigator including overall response rate (ORR), progression free survival (PFS), and overall survival (OS). |
Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion, approximately 2 years
|
|
Part 1: Effect of Food on Cmax
Tidsramme: Baseline through end of Cycle 1 (All cycles are 28 days)
|
Evaluate the effect of food on Cmax of PF-07934040 as monotherapy. |
Baseline through end of Cycle 1 (All cycles are 28 days)
|
|
Part 1: Effect of Food on Tmax
Tidsramme: Baseline through end of Cycle 1 (All cycles are 28 days)
|
Evaluate the effect of food on Tmax of PF-07934040 as monotherapy. |
Baseline through end of Cycle 1 (All cycles are 28 days)
|
|
Part 1: Effect of Food on AUClast
Tidsramme: Baseline through end of Cycle 1 (All cycles are 28 days)
|
Evaluate the effect of food on AUClast of PF-07934040 as monotherapy. |
Baseline through end of Cycle 1 (All cycles are 28 days)
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Studieleder: Pfizer CT.gov Call Center, Pfizer
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
- Lungekræft
- NSCLC
- Ikke-småcellet lungekræft
- Kolorektal cancer
- Karcinom, ikke-småcellet lunge
- Endetarmskræft
- Tyktarmskræft
- Kolorektalt karcinom
- Kolorektale neoplasmer
- KRAS
- CRC
- Ikke-småcellet lungekarcinom
- MSS CRC
- Kolorektale tumorer
- Neoplasmer, kolorektale
- pancreas duktalt adenokarcinom
- Ikke-småcellet lungekarcinom
- Ikke-småcellet lungekræft
- Karcinom, bugspytkirtelduktal
- G12V
- G12C
- KRAS-genmutation
- G12D
- G12R
- G12S
- G13D
- Q61H
- Bugspytkirtel duktalt karcinom
- Karcinom, duktal, bugspytkirtel
- Kanalcellekarcinom i bugspytkirtlen
- Kanalcellekarcinom, bugspytkirtel
- Duktalt karcinom i bugspytkirtlen
- Pancreaskanalcellekarcinom
- PADC
Yderligere relevante MeSH-vilkår
- Sygdomme i det endokrine system
- Neoplasmer efter sted
- Neoplasmer
- Tarmsygdomme
- Luftvejssygdomme
- Neoplasmer efter histologisk type
- Gastrointestinale neoplasmer
- Neoplasmer i fordøjelsessystemet
- Sygdomme i fordøjelsessystemet
- Gastrointestinale sygdomme
- Intestinale neoplasmer
- Endetarmssygdomme
- Lungesygdomme
- Neoplasmer i endokrine kirtler
- Pancreassygdomme
- Neoplasmer, kirtel og epitel
- Adenocarcinom
- Neoplasmer i luftvejene
- Thoracale neoplasmer
- Tyktarmssygdomme
- Karcinom
- Karcinom, bronkogent
- Bronkiale neoplasmer
- Neoplasmer, duktale, lobulære og medullære
- Bugspytkirtel neoplasmer
- Carcinom, Ductal
- Rektale neoplasmer
- Lungeneoplasmer
- Kolorektale neoplasmer
- Colon neoplasmer
- Karcinom, ikke-småcellet lunge
- Karcinom, bugspytkirtelduktal
- Aminosyrer, peptider og proteiner
- Proteiner
- Organiske kemikalier
- Heterocykliske forbindelser, 1-ring
- Heterocykliske forbindelser
- Heterocykliske forbindelser, 2-ring
- Heterocykliske forbindelser, smeltet ring
- Kulbrinter
- Cycloparaffiner
- Kulbrinter, alicyklisk
- Kulbrinter, cyklisk
- Terpenes
- Enzymer og coenzymer
- Antistoffer, monoklonal, humaniseret
- Antistoffer, monoklonal
- Antistoffer
- Immunoglobuliner
- Immunoproteiner
- Blodproteiner
- Serum globuliner
- Globuliner
- Uorganiske kemikalier
- Klorforbindelser
- Nitrogenforbindelser
- Koordinationskomplekser
- Guanine
- Hypoxanthines
- Purinoner
- Puriner
- Glutamater
- Aminosyrer, sur
- Aminosyrer
- Aminosyrer, dicarboxylic
- Taxoider
- Cyclodecanes
- Diterpenes
- Deoxycytidin
- Cytidin
- Pyrimidin -nukleosider
- Pyrimidiner
- Formyltetrahydrofolater
- Tetrahydrofolater
- Folinsyre
- Pterins
- Pteridiner
- Uracil
- Pyrimidinoner
- Coenzymer
- Platinforbindelser
- Albuminer
- Oxaliplatin
- Bevacizumab
- Albumin-bundet Paclitaxel
- Pemetrexed
- Cetuximab
- Gemcitabin
- Fluorouracil
- Carboplatin
- Leucovorin
- Paclitaxel
- Cisplatin
- pembrolizumab
- 130-nm albuminbundet paclitaxel
Andre undersøgelses-id-numre
- C5421001
- NCT06447662 (Registry Identifier: ClinicalTrials.gov)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .